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Background: Malaria treatment policy recommends regular monitoring of drug utilization to generate information
for ensuring effective use of anti-malarial drugs in Nigeria. This information is currently limited in the retail sector
which constitutes a major source of malaria treatment in Nigeria, but are characterized by significant inappropriate
use of drugs. This study analyzed the use pattern of anti-malarial drugs in medicine outlets to assess the current
state of compliance to policy on the use of artemisinin-based combination therapy (ACT).
Methods: A prospective cross-sectional survey of randomly selected medicine outlets in Enugu urban, southeast
Nigeria, was conducted between May and August 2013, to determine the types, range, prices, and use pattern of
anti-malarial drugs dispensed from pharmacies and patent medicine vendors (PMVs). Data were collected and
analyzed for anti-malarial drugs dispensed for self-medication to patients, treatment by retail outlets and
prescription from hospitals.
Results: A total of 1,321 anti-malarial drugs prescriptions were analyzed. ACT accounted for 72.7%, while
monotherapy was 27.3%. Affordable Medicines Facility-malaria (AMFm) drugs contributed 33.9% (326/961) of ACT.
Artemether-lumefantrine (AL), 668 (50.6%) was the most used anti-malarial drug, followed by monotherapy
sulphadoxine-pyrimethamine (SP), 248 (18.8%). Median cost of ACT at $2.91 ($0.65-7.42) per dose, is about three
times the median cost of monotherapy, $0.97 ($0.19-13.55). Total cost of medication (including co-medications)
with ACT averaged $3.64 (95% CI; $3.53-3.75) per prescription, about twice the mean cost of treatment with
monotherapy, $1.83 (95% CI; $1.57-2.1). Highest proportion 46.5% (614), of the anti-malarial drugs was dispensed
to patients for self-treatment. Treatment by retail outlets accounted for 35.8% while 17.7% of the drugs were
dispensed from hospital prescriptions. Self-medication, 82%, accounted for the highest source of monotherapy and
a majority of prescriptions, 85.6%, was adults.
Conclusion: Findings suggest vastly improved use of ACT in the retail sector after eight years of policy change,
with significant contributions from AMFm drugs. However the use of monotherapy, particularly through self-
medication remains significant with increasing risk of undermining treatment policy, suggesting additional measures
to directly target consumers and providers in the sector for improved use of anti-malarial drugs in Nigeria.
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Although malaria treatment policies are well established,
with countries in Africa adopting artemisinin-based com-
bination therapy (ACT) as first-line treatment for uncom-
plicated malaria, problems on implementation in many
settings still persist, undermining the goals of malaria
treatment policy [1,2]. Understanding the extent of these
problems is essential for generating evidence for policy
interventions to improve implementation. In Nigeria, al-
though ACT has been adopted for first-line treatment of
uncomplicated malaria since 2005, evidence abounds on
the improper use of anti-malarial drugs, such as the use of
monotherapy and other less effective anti-malarial drugs,
as well as inappropriate use of ACT [2]. This is especially
so in the retail sector where studies have reported signifi-
cant inappropriate use of anti-malarial drugs [3-6]. Since
the introduction of ACT in many countries, reports have
shown that while public sector malaria treatment has
largely conformed to policy recommendations, the private
sector is significantly characterized by inappropriate use of
anti-malarial drugs [3-7]. The use of monotherapy, inad-
equate use of ACT, fake and adulterated drugs is widely
reported, increasing the risk of treatment failures and de-
velopment of drug resistance. Reports indicated limited
access to the new agents in spite of a wide range of anti-
malarial drugs in circulation. Since introduction, ACT re-
mains the most expensive anti-malarial agent compared
to commonly used monotherapy, with a median cost of
between US$5 and $11per adult dose [8,9]. In recognition
of the role played by the private sector and the drug
supply chain on the high cost of anti-malarial drugs, the
Global Fund for HIV/AIDS, Tuberculosis and Malaria
(GFATM), in collaboration with malaria partners, intro-
duced the Affordable Medicine Facility-malaria (AMFm)
in 2009, to reduce the cost of supply and improve access
to the utilization of quality ACT in low-income countries
[10]. This was complemented with public campaigns and
targeted provider-training to increase uptake of effective
anti-malarial drugs. Furthermore, the use of artemisinin
monotherapy poses concern about the development of
resistance of malaria parasites to artemisinin derivatives
when not used in combination with partner drugs in line
with recommendations [2,11]. With a variety of anti-
malarial drugs in circulation in retail outlets, there are is-
sues with drug quality and accuracy of dosing as a result
of wide variations in brand formulations and composition
of active ingredients [2]. Irrational provision and use of
anti-malarial drugs constitutes a major risk of increasing
Plasmodium resistance to effective products and treat-
ment, undermining the goals of malaria control. Factors
that contribute to inappropriate use of anti-malarial drugs
are influenced by demand for drugs by consumers, such
as costs, lack of information about appropriate treatment
and difficulties in assessing quality treatment by patients[12]. Similarly, providers in the retail sector are often
influenced by their knowledge, financial incentives, com-
petition, perceptions of patients’ attitudes, and regulatory
sanctions [12]. Okeke et al. went further to suggest that
prescribing patterns are more likely to follow patient
demands and expectations as well as profit motive rather
than professional principles [3,5]. Adherence to anti-
malarial treatment policy by providers and patients alike is
essential to achieve the goals of the policy [4,13], and the
retail sector as a major provider of malaria treatment is
key in achieving the objectives. Since the greater number
of malaria treatment services are provided through the
private retail sector in Nigeria [14,15], as is the case in
most other developing countries, the sector represents a
greater risk of policy failure in view of significant inappro-
priate use of medicines. Appropriate attention to this sec-
tor is therefore critical to achieve the goals of malaria case
management. Regular monitoring of drug utilization, as
recommended by policy [16] becomes important when
identifying opportunities for enhancing effective imple-
mentation of the ACT policy. This study aimed to
analyse the current demand and utilization pattern of
anti-malarial drugs in medicine retail outlets in Enugu
urban, in relation to ACT policy in order to generate in-
formation for improving effective implementation of
malaria treatment policy.
Methods
Study area and population
The study was conducted in the urban city of Enugu, cap-
ital of Enugu State, southeast Nigeria. The city is popu-
lated by 722,664 inhabitants according to the 2006 census.
The population is predominantly Ibo ethnic group, who
are mainly civil servants and businessmen, with a signifi-
cant number of artisans. Of the 17 local government areas
(LGAs) of the state, three make up the Enugu urban:
Enugu East, Enugu South and Enugu North [2]. There are
two tertiary health institutions, two secondary and about
15 primary health care facilities, as well as several private
health care facilities, comprising private for-profit and pri-
vate not-for-profit organizations. There are 236 medicine
retail outlets, 75 pharmacies and 161 patent medicine ven-
dors (PMVs). Retail pharmacies and PMVs are the two
outlets licensed to sell and dispense drugs, including anti-
malarial drugs. While pharmacies are licensed to dispense
both prescription and over-the-counter (OTC) drugs,
PMVs, operated by people who have no formal training,
are licensed to sell only OTC medicines, even though they
are known to deal with a wide range of drugs [3]. Similarly
many pharmacies are either owned and/or manned by
employees who received no formal/professional training.
The study was undertaken in these two categories of retail
outlets. Malaria is a major disease burden in the area with
children and pregnant women the most vulnerable [17].
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as in most of Nigeria and artemether-lumefantrine (AL) is
first-line treatment for uncomplicated malaria since 2005.
Shortly afterwards, artesunate-amodiaquine (AA) was
added as an alternative first-line drug to AL. However, a
wide range of ACT has been registered in the country
for the first-line treatment of uncomplicated malaria,
such as dihydroartemisinin-piperaquine (DHAPQ) and
artesunate-mefloquine (ASMQ). In Enugu state there is
a free maternal and child health (FMCH) programme,
introduced by the government in 2008 to provide free
medical treatment at public health facilities for children
below five years and pregnant women. However, in spite
of the existence of free treatment policy, many house-
holds still pay for malaria treatment as a result of fre-
quent scarcity of anti-malarial drugs in government
health facilities [18].
Study design and data collection
A prospective, descriptive, cross-sectional survey was car-
ried out in medicine retail outlets comprising pharmacies
and PMVs, between the months of May and August, 2013.
A pretested questionnaire of six key questions was designed
to collect data on patients’ demographics, drugs demanded,
drugs supplied, cost of prescription, co-prescribed medica-
tions, and mode of delivery. Data were collected on anti-
malarial drugs sold to patients for self-medication (drugs
specifically requested by a patient without formal prescrip-
tion), recommendation by retail outlet, and by prescription
from a hospital. In view of the challenges and sensitive na-
ture of data collection from the retail outlets and nature of
the study, convenient sampling approach was used to pur-
posively select a representative number of outlets across
seven sections of the Enugu urban city; it was not possible
to conduct a probability sampling using a sampling frame.
However the sampling was designed to include outlet type
and utilization levels, such that outlets with extremely low
utilization were excluded. Utilization was defined as the
rate of sales of anti-malarial drugs. Outlets with fewer than
20 anti-malarial drugs per week were not considered, as
they would not be adequate to capture the pattern of drug-
use compared to those with higher rates. The outlets were
selected to cover all parts of the city and each outlet type
(pharmacy and PMV), informed by estimated number of
retail outlets in a section and expected sales of anti-malarial
drugs. 20 outlets that agreed to participate and met criteria
were initially selected during the selection period but four
were dropped due to incomplete and inconsistent data on
age, gender, anti-malarial drug and concomitant medica-
tions dispensed. Accordingly, at least two outlets (one phar-
macy and one PMV) were selected from each area, and a
total of 16 outlets were selected.
Initial visits were carried out to the outlets to discuss
the study, obtain permission and agree on date of survey.During the period, investigators observed the outlets’ rou-
tine drug dispensing and documentation processes, exam-
ined prescriptions for necessary information and updated
outlet staff on collection of appropriate information from
clients or potential patients. Trained research assistants
were engaged to participate in data collection by assisting
outlet staff in collecting relevant information. Data were
collected over ten consecutive days from each outlet over
the three-month period.
For the purposes of the study, the drugs dispensed
were categorized into three groups: those dispensed by
prescriptions from hospitals or health facilities, prescrip-
tion by the outlets (when treatment is provided by outlet),
and for self-treatment by patients (when a patient specific-
ally requests and purchases a particular anti-malarial drug,
which is taken to mean treatment that does not involve
consulting a health care provider). If a parent requested for
and purchased a particular anti-malarial drug for his/her
child from an outlet, this was considered self-treatment.
However, the limitation of this definition of self-treatment
is recognized, because some requests may have involved
recommendations from friends and associates, which is
comparable to consulting health centres [19]. It was neces-
sary to use this definition because the demand pattern was
measured by the number and type of drugs actually dis-
pensed. It should be noted that when the same drug was
available in different strengths, it was counted as one item.
Similarly, if the same drug was available by different routes
of administration, it was counted as one item. Combina-
tions of drugs were also treated as a single item.
The drugs were identified and categorized as ACT and
monotherapy based on current malaria treatment policy.
Monotherapy was further divided into artesunate mono-
therapy and non-artesunate monotherapy. Their use was
then analyzed by gender, age categories, mode/source of
treatment, and outlet type. The range, prices and cost of
treatment were similarly analyzed.
Statistical analysis
The statistical software Statistical package for Social Sci-
ence (SPSS) version 16 (SPSS Inc, Chicago, IL, USA),
was used to analyze the data. Quantitative variables were
described using appropriate summary statistics (mean,
median, standard deviation, and range); categorical vari-
ables are presented using frequency and proportions. As-
sociation between two categorical variables was assessed
using Chi-square test of independence. Data were ana-
lyzed at 5% significant level. Values of p < 0.05 were con-
sidered statistically significant.
Ethical consideration
The study received approval from the Nnamdi Azikiwe
University Teaching Hospital (NAUTH) Institutional Eth-
ical Board, as part of a larger study on the pharmaco-
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consent was obtained from staff at each outlet before
commencing the study. Where necessary a patient con-
sent was obtained before obtaining any information.Results
A total of 1,321 prescriptions were analyzed. Table 1
shows that there were more male encounters (55.9%)
than females (44.1%). The majority of cases were adult
prescriptions (85.2%), while children below the age of
five years accounted for the least number of prescrip-
tions (6.4%). ACT was received by 961 (72.7%) patients,
while monotherapy was dispensed to 27.3%. AMFm
drugs accounted for 23.5% (326) of anti-malarial drugs,
representing 33.9% of ACT. Within the monotherapy
category, artemisinin monotherapy was used in 17.8% of
cases while sulphadoxine-pyrimethamine (SP) accounted
for the highest proportion of non-artemisinin monother-
apy dispensed to 68.9% of the group. Self-medication was
responsible for the highest proportion of drug prescrip-
tions (46.1%), while prescriptions from health facilities
accounted for 18.2% of sample study.Range of anti-malarial drugs
A wide range of anti-malarial drugs was identified in a
total of 13 different regimens, comprising over 75 brandsTable 1 Demographic characteristics and summary
findings





Below 5 74 6.4
5 to 12 113 8.4




Artemisinin monotherapy 64 17.8




Outlet treatment 473 35.7
Prescriptions 234 18.2
5 Average number of brands per
outlet (standard deviation)
18 (±4.47)
ACT = artemisinin combination therapy; PMV = patent medicine vendor;
AMFm = Affordable Medicine Facility–malaria.of products, including tablets, suspensions and injections.
Each outlet stocked an average of 18 (±4.47) brands. The
number and frequency of use of the different types and
combinations of anti-malarial drug regimens are shown in
Figure 1. AL brands were the single most used regimen at
50.6% (668), followed by SP and DHAPQ at 18.8 and
12.9%, respectively. Chloroquine (CQ), proguanil (PL) and
mepacrine (MEP) were the least used agents, as shown in
Figure 1. ACT was available in six different combinations
or regimens, accounting for the widest range of anti-
malarial drugs dispensed. AL brands made up the highest
number of brands within the entire anti-malarial regi-
mens. AMFm drugs were found in every outlet surveyed.
Utilization pattern
Table 2 shows the distribution of anti-malarial drugs by
category, their mode of treatment and the pattern of use.
Pattern of use was measured by the proportion of anti-
malarial drug-use between ACT and monotherapy in
each category. Females were more likely to use ACT
(74.3%) than males (71.3%), although this was not statisti-
cally significant (p >0.05). Across the age groups, children
were more likely than adults to use ACT (OR = 3.81; p <
0.0001). Use of ACT under the treatment modes shows
that the highest proportion of use occurred among hos-
pital and outlet prescriptions, at 91% (218/204) and 90%
(425/472), respectively, while monotherapy was used most
under self-medication by patients (47.4%). In retail outlets,
there was little difference between the pharmacies,
(74%) and the PMVs (70.7%) in the use of ACT, which
was not statistically significant (p > 0.05). As shown in
Table 2, the highest proportion of AMFm drugs (54/
102) as ACT was used in children aged five to 12 years.
In adults over 12 years old, AMFm represented only
31% of ACT dispensed.
Table 2 also shows that hospital prescriptions were the
highest source of anti-malarial treatment for children
aged below five years, at 40% compared to other modes,
followed by outlet prescriptions. Only 16% of adult doses
were dispensed from hospital prescriptions.
Study identified five different combinations or regi-
mens of ACT and analysis showed that the AL brand
was the most used ACT given to 70% (961) of the group.
This was followed by DHAPQ (17.7%) and AA (8.7%)
regimens, respectively.
The AMFm drugs were used most through outlet
prescriptions where they accounted for 39% (165) of
ACT dispensed under this mode. They represented
44% (162) of ACT dispensed through PMVs, and 27.6%
through pharmacies.
Co-prescribed medication
Some 70% (919) of dispensed drugs contained at least
one concomitant medication. Some 51.7% (671/1,321) of
Figure 1 The utilization pattern of anti-malarial drugs dispensed, by types. AA = artesunate-amodiaquine; AL = artemether-lumefantrine;
AQ = amodiaquine; AS = artesunate; ASMF = artesunate-mefloquine; ASSP = artesunate-sulphadoxine + pyrimethamine; CHLQ = chloroquine;
DHAPQ = dihydroartemisin-piperaquine; HF = halofantrine; MEP =mepacrine; PL = proguanil; QN = quinine; SP = sulphadoxine + pyrimethamine.
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concomitant medication, followed by antibiotics given to
18% (248/1,321) of the patients. Vitamin preparations
were contained in 16.5% (218) of co-prescribed medica-
tions. Up to five drugs were used per patient at a median
of one drug per patient. The majority of hospital pre-
scriptions, 85% (195/240), contained concomitant medi-
cations while the least co-medications were observed for
children between five and 12 years old, 54% (60/111).Table 2 Distribution of anti-malarial drugs and mode of treat
treatment
Gender Age group
Male Female <5 years 5-12 years ≥13 yea
n (%) n (%) n (%) n (%) n (%)
Drug category
ACT 527 (71.4) 434 (74.3) 74 (87.1) 102 (91.9) 785 (70.
Monotherapy 211 (28.6) 149 (25.6) 11 (12.9) 9 (8.1) 340 (30)
Total 738 583 85 111 1125
Treatment mode
Prescription 132 (17.9) 108 (18.5) 34 (40.0) 25 (22.5) 181 (16.
Recommendation 263 (35.6) 209 (35.9) 31 (36.5) 44 (39.6) 397 (35.
Self-treatment 343 (46.5) 266 (45.6) 20 (23.5) 42 (37.9) 547 (48.
Total 738 583 85 111 1125
AMFm 170 (32.2) 156 (36.0) 30 (40.5) 54 (53) 242 (31)
ACT = Artemisinin Combination Therapy; PMV = Patent Medicine Vendor.Drug prices and costs of medication
Table 3 presents the median prices of anti-malarial drugs
as well as the mean/median cost of treatment including
co-medication. Altogether, anti-malarial drug prices ranged
from $0.19-13.55, at a median cost of $2.26 per dose. ACT
was the most expensive with a median cost of $2.9 per
dose ($0.65-7.42). This translates to three times the median
cost of monotherapy at $0.97($0.19-13.55). AMFm drugs
cost between $0.65 and 2.58 at a median price $1.94 perment across demographic groups and sources of




n (%) n (%) n (%) n (%) n (%)
0) 318 (52.2) 425 (90.) 218 (90.8) 594 (74.1) 367 (70.7)
291 (48.8) 47 (10.0) 22 (9.2) 208 (25.9) 152 (29.5)
609 472 240 802 519
1) - - - 138 (17.2) 102 (19.6)
3) - - - 262 (32.7) 210 (40.5)
6) - - - 402 (50.1) 207 (39.9)
802 519
100 (32) 165 (39) 61 (28) 164 (27.6) 162 (44)
Table 3 The median prices and drug treatment costs of anti-malarial drugs in the surveyed retail outlets, across
categories
Drug price (Naira) Treatment cost (Naira)
Variable Median Range Median Range Mean 95% CI
Anti-malarial drugs 350 30-2,100 420 50-4,800 496.77 478.03-515.51
ACT 450 100-1,150 500 100-2,600 575.78 557.48-594.08
Monotherapy 150 30-2,100 175 50-4,800 285.86 244.60-327.12
AMFm 300 100-450 345 100-1,700 349.82 335.82-363.81
Gender
Male 350 50/1,550 420 60–2,670 500.49 476.56-524.42
Female 350 30/2,100 410 50-4,800 492.07 462.23-521.91
Age group
Under 5 300 100/1,250 450 100-2,250 556.24 470.49-641.98
5-12 yrs 250 70/900 320 70-1,400 397.39 351.83- 442.95
over 12 350 30/2,100 420 50-4,800 502.08 481.59-522.58
Treatment mode
Prescription 490 70/2,100 560 90-4,800 678.25 619.73-736.77
Outlet treatment 350 60/1,900 450 70-1,900 508.99 485.86-532.14
Self-medication 300 30/1,550 320 50-2,670 415.78 389.62-532.14
Outlet type
Pharmacy 350 30/2,100 450 50-4,800 548.61 521.61- 575.61
Patent medicine vendor 300 70/1,500 380 70-1,650 416.67 395.20-438.14
ACT = artemisinin-based combination therapy; AMFm = Affordable Medicine Facility-malaria; US$1 = N155.
Ezenduka et al. Malaria Journal 2014, 13:243 Page 6 of 10
http://www.malariajournal.com/content/13/1/243dose. Differences in the median prices and costs of
treatment are reflected across the various groups and
categories. While the lowest median price of $1.61 per
anti-malarial drug and lowest treatment cost of $2.06
was recorded for children between five and 12 years, the
highest price and cost of treatment was estimated for
the hospital prescription mode at $3.16 and $3.61,
respectively.
The total cost of medication (including co-medications)
with ACT averaged $3.64 (95% CI; $3.53-3.75) per case,
which is about twice the mean cost of treatment with
monotherapy, at $1.83 (95% CI; $1.57-2.1). The average
medication cost differed remarkably across age categories.
While it was highest for children under five years at $3.32
(95% CI; $2.76-3.86), the lowest was observed for children
aged between five and 12 years at $2.44 (95% CI; $2.16-
2.72). Total medication cost also showed significant differ-
ences across treatment modes, with hospital prescription
having the highest cost at $4.18 (95% CI; $3.81-4.55). Self-
treatment had the least medication cost at $2.66 (95% CI;
$2.50-2.83) per case.
Discussion
This study, unlike previous studies, relied on actual drug
utilization data to assess implementation of malaria treat-
ment policy in the retail sector. Compared to previous
studies [2], findings suggest vastly improved use of ACTin the sector, some eight years after the introduction as
the first-line treatment for uncomplicated malaria in
Nigeria. The study by Mangham et al. in 2009, about five
years after policy change in the same area suggested
utilization rate of 24.2% for ACT in medicine outlets using
patients’ exit questionnaires [2]. Findings corroborate the
results of previous, related studies in the area in terms of
availability and utilization of anti-malarial drugs [2,5,6,8].
Prescriptions were mostly adults, while children cases
were limited, comprising prescriptions from hospitals.
Predominance of adult prescriptions agrees with previ-
ous findings that adults make more use of retail outlets
than children [1,7]. The study shows that AL, as the pol-
icy first-line drug in Nigeria, is the most commonly used
ACT followed by DHAPQ, corroborating the studies in
2009 by Magham et al. [2] and in 2010 by Uzochukwu
et al. [6], which documented similar findings for both
public and private health facilities in the same area.
Studies in Uganda and Zambia also suggested prefer-
ence for AL regimen over other ACT in health facilities
[20]. The use of AA brands in this study appears quite
limited at 8.7% of ACT even though it was the alterna-
tive first-line drug in Nigeria. Safety concerns associated
with the use of AA is the possible reason for this, in
addition to availability of a wide range of other ACT.
AA has been associated with varying degrees of side-
effects, which have limited its use, especially in adult
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ation of efficacy and/or safety in the study environment.
Other likely factors include availability of formulations and
promotional activities of pharmaceutical companies oper-
ating in the country. In consequence, the AL regimen had
the widest range of brands in the study as well as the most
available. The high proportion of dispensed ACT, there-
fore, indicates a positive development on the part of retail
outlets in the provision of malaria treatment. This can be
attributed to several interventions that have been imple-
mented in the sector to enhance appropriate use of
anti-malarial drugs. These include the introduction of
AMFm drugs accompanied by public campaigns and
targeted provider trainings to enhance uptake of effective
anti-malarial drugs, as well as community-based interven-
tions [2,10]. The appreciable presence of AMFm drugs,
which accounted for up to 23% of dispensed anti-malarial
drugs, reinforced the use of ACT based on affordable
prices. Consequently, their use impacted positively on
prices and costs of treatment.
The study indicates that monotherapy, either as
artemisinin- or non-artemisinin-based monotherapy
was used significantly at 27% in the retail sector. The
use of artemisinin-based monotherapy is contrary to
policy recommendation in view of potential risk of para-
site resistance as a result of its short half-life [11]. The
extent of monotherapy in this study suggests substantial
inappropriate use of anti-malarial drugs, which under-
mines treatment goals by promoting development of
drug resistance and treatment failures, and should be a
cause for concern. Analysis suggests that monotherapy
was used more in adults and in PMVs, and obtained
mostly through self-medication. This points to the need
for more public education for appropriate use of anti-
malarial drugs and better-targeted strategy to improve
the use of ACT through PMVs and pharmacy sales staff,
since they are known to command a significant popula-
tion seeking malaria treatment in Nigeria [4,15]. Reason
for use may be attributed to the higher costs of ACT,
availability of monotherapy agents and lack of adequate
information on appropriate use of effective anti-malarial
drugs. This situation is likely to be worse in rural areas
where the level of awareness is lower and choice may be
more limited [21].
The extent of monotherapy is reinforced by the
prevalence of self-medication as the highest source of
drug utilization in this study. This was not surprising
because previous studies have documented widespread
self-medication among patients with anti-malarial drugs
obtained from retail outlets, in most developing countries
[15,19,24]. It was therefore expected that self-medication
was the highest source of monotherapy, due to lack of ad-
equate knowledge of effective anti-malarial drugs on the
part of consumers, leading to inappropriate use of drugs.Self-treatment may be attributed to previous experience
with a particular drug, such as having used the same drug
for similar symptoms, or neighbour, friend, or relative pre-
viously taking the same drug for similar symptoms [25].
Self-medication, which is mostly based on presumptive
diagnosis, will similarly be faced with consequences of
misdiagnosis, over-treatment of malaria, masking of
underlying, potentially fatal conditions and unnecessary
side-effects [26,27]. This reinforces the increasing calls
for interventions to improve treatments from these out-
lets through regular education programmes [3,12,28].
Outlet prescriptions reflect malaria treatment practices
in medicine outlets, in terms of the use of ACT and
findings suggest significant use of ACT, especially in
pharmacies. This indicates positive impact of educa-
tional programmes on effective malaria treatment im-
plemented in the past, as part of intervention strategies
to educate private providers. It is expected that regular
training of these providers translates to appropriate use
of anti-malarial drugs. However the extent of monother-
apy use in this study, especially through the PMVs, sug-
gests the need for reinforced and regular training and
education for these providers on effective use of anti-
malarial drugs. The little difference in the use of ACT
between the pharmacies and the PMVs is notable and
can be explained by the significant presence of sales staff
who do not have formal training, and which is expected to
impact on service delivery through pharmacies. The suc-
cesses achieved so far with the training programmes point
to the usefulness of targeted interventions. Evidence of
improved performance of the providers through targeted
training has been demonstrated in studies carried out in
Kenya and Tanzania [28-30]. Prescriptions from hospitals
which consists almost entirely of ACT is consistent with
findings that the public sector conforms more to policy on
the use of ACT and that prescribing pattern is not influ-
enced by patient demand, compared to the private retail
sector [3,5,6]. Fewer cases of monotherapy prescription
through this mode may be explained by the use of SP for
prophylaxis in pregnancy. This may have contributed to
making SP the highest used monotherapy in this study.
A major issue of concern in malaria treatment through
the retail sector is presumptive treatment. Studies have
shown that treatment through the medicine outlets is
mostly based on clinical symptoms and this has been
shown to result to over 50% being non-malaria cases
[6,15], leading to wastage and inappropriate management
of fevers and other complications. Although data was not
comprehensively collected on laboratory diagnosis in this
study, evidence suggests that the majority of malaria treat-
ment was not supported by laboratory diagnosis. This is
reinforced by the fact that anti-malarial drugs are treated
as OTC medicines and the use is not regulated as pre-
scription, even though regulation of drug sales in Nigeria,
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patients undertake diagnostic tests for malaria in private
laboratories before visiting the outlets for treatment,
sometimes with prescriptions from laboratory attendants
[31]. This study suggests a high level of presumptive mal-
aria treatment, which encourages the use of wrong drugs,
limiting the use of effective anti-malarial drugs. Patient de-
mand for diagnostic testing was limited, in addition to
limited accessibility of laboratory services. Policy should,
as a matter of urgency, consider the introduction of rapid
diagnostic tests (RDT) in retail outlets to enhance accur-
acy and efficiency of malaria treatment in the sector. The
World Health Organization (WHO) current approach to
effective malaria treatment emphasizes the ‘test, treat and
track’ (TTT) strategy, which translates to malaria diagno-
sis, early treatment with effective anti-malarial drugs and
follow-up monitoring to ensure effective implementation.
Even though this study may not have adequately cap-
tured the extent of co-medication in the study, analysis
indicates a substantial degree of concomitant treatment
with other drugs. Understandably, analgesics were the
most frequently used, followed by antibiotics with implica-
tions for increased cost of treatment. Vitamin preparations
were the third most used co-medication. Analgesics are
often required to relieve accompanying fevers and pains in
malaria infection even though many cases actually resolve
with effective anti-malarial drugs. The use of vitamin
preparations, especially those containing minerals and
trace elements (such as zinc, iron (Fe2+), copper, etc) with
anti-oxidant properties has implications for the effective-
ness of ACT. Anti-oxidants, vitamin C and vitamin E have
been found to interfere with artemisinin compounds,
thereby reducing their efficacy [32,33]; the advice is they
are used after the completion of ACT dose, if needed [34].
The extent of concomitant medication in this study
indicates substantial wastage when viewed against the
prevalence of presumptive treatment of malaria which, in
addition increases inefficiency in malaria treatment.
Co-medication with antibiotics was apparently based on
presumptive co-morbidity with mostly typhoid fever,
which is often informed by previous laboratory findings
and experiences, while a few are informed by laboratory
tests accompanying malaria treatment requests. Wide-
spread co-medication with antibiotics has implications
for safety in view of the potential for drug-drug interac-
tions and other safety concerns. Antibiotics are known
to have high incidence of adverse events, such as rashes
and pruritus, which might even be attributed to the new
anti-malarial drugs [21]. This study suggests that children
aged below five years are more likely to be prescribed co-
medication. The study in Ghana reported similar findings
where children below five received more co-prescribed an-
tibiotics than other age categories [21]. Co-morbidity with
pneumonia and related conditions is commonly associatedwith childhood malaria, which informed earlier recom-
mendation for symptomatic treatment of childhood fevers
with a combination of anti-malarials and antibiotics [26].
The lower proportion of co-medication in this study com-
pared to the Ghana study may be explained by the fact
that the retail sector is characterized by self-medication,
where the choice and number of drugs may be limited by
cost of treatment. It is also very likely that this study did
not capture all co-medications used among the cohorts,
for some reasons. Many patients may still have other med-
ications such as analgesics and multivitamins which are
routinely used mostly in children. This is particularly so
for prescriptions dispensed through self-medication. The
use of antibiotic co-prescription would suggest less con-
fidence of actual diagnosis of malaria, hence prescribing
anti-malarials would be a ‘cover’ for potential infection
or to prevent subclinical infection becoming manifest
[21]. Similar findings were reported from a study in
Tanzania for patients with a history of cough for which
anti-malarials were prescribed [35]. The issue of con-
comitant medication also contributes to irrational use of
anti-malarial drugs due to polypharmacy and increased
cost of care. Just as in many other studies, over-use of
medication in malaria treatment results in polypharmacy,
encouraging poor adherence in addition to the risks of
drug interactions, adverse drug reactions and in conse-
quence, treatment failures.
Study findings suggest significant reductions in prices
and costs of treatment based on previous studies. The
study by Mangham et al. [2] on the treatment of uncom-
plicated malaria (five years after introduction of ACT)
showed the median cost of adult dose of ACT in the retail
outlets to be N600 (US$3.87). A previous study in 2010
showed a median price of the ACT to be N700 (US$4.52)
per adult dose [8]. The current price of N400 (US$2.67)
per adult dose therefore suggests a significant reduction
from previous prices. This can easily be attributable to the
penetration of AMFm drugs which showed wide utilization
across ages and gender. However, at a median cost of $1.94
per adult dose, the current prices of AMFm drugs are still
well above intended targets of US$0.42-1.00 to achieve
expected goals [10]. Available information suggests limited
availability of AMFm products below their market demand
and as a result, are sold at costs higher than recommended
prices, in response to market forces. The median cost of
ACT at US$2.67 per adult dose remains high and unafford-
able for many low-income patients who therefore resort to
cheaper monotherapy, thus contributing to the incidence
of monotherapy.
Limitations
Although significant information was obtained from this
study, there were limitations that need to be highlighted
to better interpret and use the information. Although
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patient turnover, the pattern of utilization which cuts
across different parts of the city reflects health-seeking
behavior of patients using retail outlets and therefore
likely represents sample population with malaria in the
city [21]. The study did not collect further information
to accurately analyze the use of monotherapy and deter-
mine those that were used appropriately for prophylaxis
in pregnancy and children, as well as those purchased to
complete a dose in single-dose combination. Similarly, in-
formation on laboratory diagnosis following anti-malarial
drug treatment was not adequately collected due to incon-
sistency and this would have helped inform a more com-
prehensive analysis of the drug use pattern in the retail
sector. Due to the challenges of data collection in the re-
tail sector and their unwillingness to volunteer informa-
tion, data may be incomplete and potentially unreliable;
hence, the use of large data to enhance precision and the
validity of findings, in addition to the use of trained field
staff to assist outlet staff in data collection. In spite of
these limitations study findings largely reflect the pattern
of anti-malarial drug utilization in the retail sector.Conclusion
This study suggests a vastly improved and substantial up-
take of ACT as the anti-malarial drug of choice for the
first line treatment of uncomplicated malaria in medicine
retail outlets in Nigeria, eight years after policy change.
This portends positive development towards achieving the
goals of malaria treatment, considering the challenges of
the sector. Evidence suggests positive contributions from
the AMFm drugs, which was accompanied by targeted
education programmes to improve the use of effective
anti-malarial drugs, as well as the availability of a wide
range of ACT. However the use of monotherapy and inef-
fective drugs remain significantly high due mainly to the
prevalence of self-medication as the predominant mode of
malaria treatment in the sector, in addition to poor treat-
ment practices of providers. This would certainly lead to
increasing risk of development of parasite resistance to ef-
fective anti-malarial drugs and treatment failures, thereby
undermining the goals of malaria treatment policy. In
view of the challenges of the sector, characterized by
self-medication and the presence of poorly informed
providers, there is need for improved targeting of the
general public and the retail providers for enhanced and
sustained education on effective use of anti-malarial
drugs. This is crucial if the goals of malaria treatment
policy are to be achieved, considering the role of the
sector in the provision of malaria treatment in Nigeria.Competing interests
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